glp 1 agonist cardiovascular outcomes Results of trials comparing GLP-1 receptor GLP-1 Agonists in Cardiovascular Diseases:

Personalized Treatment Options Available At Cape Fear Physical Medicine.

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

Differences between GLP1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) ...

This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database

Intention-to-treat analyses resulted in an HR of 1.36 (95% CI 0.51, 3.61)

Mounjaro and Ozempic both help control blood sugar and promote weight loss in people with diabetes